NCT00043394 - CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2002

Primary Completion Date

October 31, 2003

Study Completion Date

October 31, 2003

Conditions

Carcinoma, Breast

Interventions

DRUG

0.04 mg/kg CpG 7909

0.04 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks

DRUG

Herceptin®

Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.

DRUG

0.08 mg/kg CpG 7909

0.08 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks

DRUG

Herceptin®

Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.

DRUG

0.12 mg/kg CpG 7909

0.12 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks

DRUG

Herceptin®

Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.

DRUG

0.16 mg/kg CpG 7909

0.16 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks

DRUG

Herceptin®

Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.

Trial Locations (12)

33324

Pfizer Investigational Site, Plantation

44195

Pfizer Investigational Site, Cleveland

48109

Pfizer Investigational Site, Ann Arbor

48202

Pfizer Investigational Site, Detroit

92262

Pfizer Investigational Site, Palm Springs

92868

Pfizer Investigational Site, Orange

94704

Pfizer Investigational Site, Berkely

06510

Pfizer Investigational Site, New Haven

20007-2197

Pfizer Investigational Site, Washington D.C.

48126-2641

Pfizer Investigational Site, Dearborn

48322-3013

Pfizer Investigational Site, West Bloomfield

05401-3456

Pfizer Investigational Site, Burlington